drugset / Trial / NCT01925313

A Randomized, Open Label, Three-Treatment, Three-Period, Six-Sequence Crossover Study To Compare Safety and Pharmacokinetic Properties of CJ-30044 and Bepotastine Besilate and To Investigate Food-effect on Pharmacokinetics of CJ-30044 in Healthy Adult Male Volunteers

NCT01925313

Phase 1 Completed 30 enrolled HK inno.N Corporation
RandomizedCrossoverOpen-labelTreatment

Summary

Study objectives * To compare the safety and pharmacokinetic properties of CJ-30044 and bepotastine besylate after a single oral administration in healthy male volunteers. * To evaluate the food-effect on pharmacokinetics of CJ-30044 after a single oral administration in healthy male volunteers.

Timeline

Start
2012-12
Primary completion
2013-02
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Bepotastine Small molecule 10 mg Oral
Subject CJ-30044 Unknown 20.51 mg Oral

Indications

No indication recorded.